[Introduction to meta-analytic methodology]
- PMID: 7569424
- DOI: 10.1016/0248-8663(96)80751-x
[Introduction to meta-analytic methodology]
Abstract
General considerations about meta-analysis and the different steps of this technique are successively discussed: definition of the main objective, identification of the outcome, description of the retrieval and selection of trials, description of the statistical analysis and interpretation of the results. Advantages and drawbacks of the meta-analytical technique are then described: 1) scientific approach, possible quantification of the therapeutic effect, increase of the power of a future clinical trial, synthesis of contradicting results, assessment of the homogeneity, subgroup analysis, analysis of sensibility, scientific collaboration, help for therapeutic information. 2) retrospective approach, inconsistency among trials, potential biases, persistence of some unsolved methodological problems, difficulties for a critical reading and for the interpretation of conclusions. In addition, some examples of published meta-analyses are given to illustrate the advantages and limits mentioned above.
Similar articles
-
Meta-analyses of randomised clinical trials in oncology.Lancet Oncol. 2001 Aug;2(8):475-82. doi: 10.1016/S1470-2045(01)00453-3. Lancet Oncol. 2001. PMID: 11905723 Review.
-
Critical reading of the meta-analysis of clinical trials.Therapie. 1995 Jul-Aug;50(4):339-51. Therapie. 1995. PMID: 7482388 Review.
-
Primer: strengths and weaknesses of meta-analysis.Nat Clin Pract Rheumatol. 2008 Mar;4(3):146-52. doi: 10.1038/ncprheum0732. Nat Clin Pract Rheumatol. 2008. PMID: 18227829 Review.
-
[Critical reading of clinical trials].J Fr Ophtalmol. 2011 Dec;34(10):755-61. doi: 10.1016/j.jfo.2011.06.002. Epub 2011 Oct 11. J Fr Ophtalmol. 2011. PMID: 21992992 Review. French.
-
Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials.Am J Gastroenterol. 2009 Mar;104(3):546-51. doi: 10.1038/ajg.2008.22. Am J Gastroenterol. 2009. PMID: 19262513
Cited by
-
Phosphodiesterase III inhibitors for heart failure.Cochrane Database Syst Rev. 2005 Jan 25;2005(1):CD002230. doi: 10.1002/14651858.CD002230.pub2. Cochrane Database Syst Rev. 2005. PMID: 15674893 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources